Investment Rating - The report indicates a positive investment sentiment with a focus on buying the dip in US equities, particularly in single stocks, which saw significant inflows [9][18]. Core Insights - Institutional and retail clients were net buyers of US equities, with a notable $4.1 billion inflow into single stocks, marking the fifth highest weekly inflow since 2008 [9][18]. - The report highlights a shift back to large-cap stocks, with inflows observed across all market cap sizes, particularly in Communication Services and Health Care sectors [9][18]. - Hedge funds continued to sell US equities for the fifth consecutive week, contrasting with the buying behavior of institutional and retail clients [9][18]. Summary by Sections Client Flows - Institutional clients led the buying activity, marking the largest weekly inflow since November 2022, while retail clients also participated after a period of selling [9][18]. - Hedge funds were the largest net sellers, with cumulative flows showing a significant outflow trend [5][22]. Sector Performance - Inflows were recorded across all 11 sectors, with Communication Services and Health Care leading the way, alongside notable inflows in the Energy sector [9][18]. - The report notes that clients sold equity ETFs for a second week, with outflows primarily from Tech and Materials sectors, while defensive sectors like Health Care and Real Estate saw inflows [9][18]. Size Segmentation - All market cap segments (large, mid, small) experienced inflows, with small caps showing resilience with inflows in five of the last seven weeks [9][18]. - The report indicates a preference for small-cap and value ETFs, contrasting with the outflows from large and mid-cap ETFs [9][18]. Corporate Buybacks - Corporate buybacks have slowed but are expected to pick up during the earnings season, with a focus on Tech and Financials dominating the buyback activity over the last three months [9][18].

Joining us now, a Democratic Congressman from Maryland, Glenn Ivy, who represents about 65,000 federal workers. Congresswoman, welcome. Um, you just heard AOC there.Do you agree with her that Democrats are looking for a long-term solution. They don't want any kind of a quick band-aid fix. Well, I think her uh political analysis is right there for sure.And couple points in addition, keep in mind that when it came to extending the tax cuts for the wealthiest Americans, the House Republicans and the Senate Rep ...

Business Expansion - One Medical is expanding into pediatric care [1] - One Medical launches a new pay-per-visit virtual health service for children ages 2 to 11 [1] Pricing and Services - Message-based visits start at $29 [1] - Video calls start at $49 [1] - The service treats common conditions like pink eye, eczema [1]

Core Insights - The Healthtech sector is experiencing a significant shift towards AI-enabled provider operations, which accounted for 44% of overall Healthtech investment in 2025, marking the highest investment levels since 2022 [1][2] - A total of $5.5 billion has been invested in healthcare provider operations, with projections indicating a full-year investment of $8.25 billion, surpassing the previous record of $7.8 billion set in 2021 [1][6] - The focus of investment is shifting from clinical care to operational tools, as AI is utilized to enhance efficiency in healthcare delivery [1][4] Investment Trends - Provider operations have seen a dramatic increase in investment, rising from 19% of Healthtech investment four years ago to nearly 50% in 2025 [1][6] - Alternative care investment has decreased significantly, accounting for only 9% of Healthtech investment in 2025, down from 42% in 2021 [1][6] - The total expected investment in Healthtech by the end of 2025 is projected to reach $18.5 billion [6] M&A Activity - There have been 32 mergers and acquisitions (M&A) deals in provider operations in 2025, with consolidation becoming a key exit strategy for investors [6] - 52% of the deals in 2025 have involved AI technologies, indicating a strong trend towards integrating AI in Healthtech [6] Valuation Insights - Generalist investors have added a valuation premium of 22% to mega-deals, which represent 38% of total Healthtech investment this year [6] - Seed-stage AI valuations have increased by approximately 42% since 2021, reflecting growing confidence in AI solutions [6] Trust in AI - Physicians express a high level of trust in AI for work efficiency (75%), but show significant concern regarding patient privacy, with only 15% trusting AI in this aspect [6]

Market Overview - U.S. stock futures were higher, with Dow futures gaining over 100 points on Thursday [1] Company-Specific Movements - Satellogic Inc. (NASDAQ:SATL) shares fell 13.1% to $3.60 in pre-market trading following a proposed public offering [1] - American Battery Technology Company (NASDAQ:ABAT) shares dipped 23.9% to $6.81 after the DOE terminated a grant [3] - Hyperfine, Inc. (NASDAQ:HYPR) shares decreased 14.1% to $1.89 due to preliminary third-quarter revenue results falling below estimates and a proposed public offering [3] - Omeros Corporation (NASDAQ:OMER) shares declined 9.2% to $9.45 after a significant 154% increase the previous day following Novo Nordisk's acquisition of its global rights to Zaltenibart [3] - Hewlett Packard Enterprise Company (NYSE:HPE) tumbled 8.6% to $22.85 despite reporting record revenue driven by AI demand, as restructuring costs compressed profit margins [3] - NIO Inc. (NYSE:NIO) fell 8.5% to $6.24 in pre-market trading [3] - Inventiva S.A. (NASDAQ:IVA) declined 7.5% to $5.06 after a 10% gain the previous day [3] - Bitfarms Ltd. (NASDAQ:BITF) fell 4.6% to $6.17 after announcing a $300 million convertible senior notes offering [3] - Rigetti Computing, Inc. (NASDAQ:RGTI) shares fell 4.8% to $53.66 following CEO Subodh K. Kulkarni's sale of 1,000,000 shares, raising concerns about leadership commitment [3] - Datavault AI Inc. (NASDAQ:DVLT) slipped 4.8% to $2.00 in pre-market trading [3]

Group Financial Performance and Strategy - Merck aims to drive sustainable value creation as a leading science & technology company[7] - The company is actively managing its portfolio, focusing on attractive markets and solid competitive positions, with >80% of businesses in each category[10, 11] - Merck confirms M&A guardrails and financial discipline, with ongoing scouting for further M&A to accelerate growth[18] - The company is committed to topline growth and margin expansion mid-term[72] - Merck is on track to meet its 2025 guidance and has a positive early indication for 2026, with an expected EBITDA pre margin of ~29% in 2025[69, 70] Key Growth Drivers - Key growth drivers explain up to 80% of future growth, focusing on secular growth markets[20] - Process Solutions market segment continues to grow at a 9% to 10% CAGR[37] - Semiconductor Solutions contribute over 80% to Electronics sales mid-term[50] - Healthcare mid-term growth ambition is raised, driven by Rare Diseases uptake, targeting LSD to MSD organic sales growth (CAGR in %)[46] Life Science Strategy - Life Science is centering the business on three distinct go-to-market approaches: Process Solutions (~€35 billion), Advanced Solutions (~€47 billion), and Discovery Solutions (~€29 billion)[32]

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified class period from February 26, 2025, to August 5, 2025 [1][2]. Summary by Relevant Sections Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, which could jeopardize PYLARIFY's price point and revenue growth [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the class period [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative of the class or may choose to remain absent [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group with the largest financial interest [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Insights - Elevance Health, Inc. (ELV) is scheduled to report its Q3 2025 results on October 21, 2025, with earnings estimated at $4.97 per share and revenues of $49.5 billion [1][6] Earnings Estimates - The earnings estimate for Q3 2025 has seen one upward revision and two downward revisions, indicating a year-over-year decline of 40.6% [2] - The revenue estimate for Q3 2025 suggests a year-over-year increase of 10.7% [2] - For the full year 2025, the revenue consensus is $197.36 billion, reflecting a 12.6% year-over-year rise, while the EPS consensus is $29.96, indicating a 9.3% year-over-year decrease [3] Earnings Performance - Elevance's earnings have beaten the consensus estimate in two of the last four quarters, with an average surprise of negative 2.3% [3] Earnings Prediction Model - The current Earnings ESP for Elevance is +3.36%, but it holds a Zacks Rank of 4 (Sell), making an earnings beat uncertain [4] Revenue Drivers - The consensus estimate for product revenues indicates a 7.7% growth from the previous year's $5.9 billion, while premiums are expected to increase by 11.5% year-over-year [5][6] Cost and Expense Outlook - Elevated costs and benefit expenses are anticipated to impact profit margins negatively, with total expenses expected to rise around 9% year-over-year in Q3 [9] - The benefit expense ratio is estimated at 91.6, higher than the previous year's 89.5 [9] Segment Performance - The Health Benefits segment's operating income is projected to decrease by 45.5% year-over-year, with declining Medicaid memberships affecting premium growth [10]

Core Viewpoint - Raymond James maintains an "Outperform" rating for Johnson & Johnson and raises its price target from $174 to $209, reflecting confidence in the company's future performance [1][5] Group 1: Financial Performance - Johnson & Johnson recently increased its 2025 sales forecast after a strong quarterly earnings report that exceeded Wall Street's expectations [2][5] - The company's stock is currently trading at $190.85, with a slight decrease of 0.05, reflecting a percentage change of approximately -0.03% [3] - Over the past year, JNJ has reached a high of $194.40 and a low of $140.68, showcasing its resilience in the market [3] Group 2: Market Position - Johnson & Johnson's market capitalization stands at approximately $459.63 billion, indicating its significant presence in the healthcare industry [4] - The stock has a trading volume of 11.27 million shares, reflecting investor interest and confidence in the company's future performance [4] Group 3: Strategic Moves - The company's strategic decision to spin off its orthopedics business into a standalone entity is expected to contribute to its growth prospects [2][5]

Core Viewpoint - A class action lawsuit has been filed against WPP plc for alleged violations of the Securities Exchange Act, claiming the company made false and misleading statements regarding its revenue forecasts and client retention [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from February 27, 2025, to July 8, 2025, with a deadline for shareholders to act by December 8, 2025 [2]. - The complaint alleges that WPP misled investors about its ability to forecast revenue and growth, asserting it had a strong basis for its projections, which it ultimately failed to meet [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress at no cost [3]. Group 3: DJS Law Group's Focus - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, aiming to enhance investor returns through advocacy [4].